425 reports of this reaction
1.2% of all NOREPINEPHRINE BITARTRATE reports
#20 most reported adverse reaction
METABOLIC ACIDOSIS is the #20 most commonly reported adverse reaction for NOREPINEPHRINE BITARTRATE, manufactured by Deseret Biologicals, Inc.. There are 425 FDA adverse event reports linking NOREPINEPHRINE BITARTRATE to METABOLIC ACIDOSIS. This represents approximately 1.2% of all 35,563 adverse event reports for this drug.
Patients taking NOREPINEPHRINE BITARTRATE who experience metabolic acidosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
METABOLIC ACIDOSIS is a less commonly reported adverse event for NOREPINEPHRINE BITARTRATE, but still significant enough to appear in the safety profile.
In addition to metabolic acidosis, the following adverse reactions have been reported for NOREPINEPHRINE BITARTRATE:
The following drugs have also been linked to metabolic acidosis in FDA adverse event reports:
METABOLIC ACIDOSIS has been reported as an adverse event in 425 FDA reports for NOREPINEPHRINE BITARTRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
METABOLIC ACIDOSIS accounts for approximately 1.2% of all adverse event reports for NOREPINEPHRINE BITARTRATE, making it a notable side effect.
If you experience metabolic acidosis while taking NOREPINEPHRINE BITARTRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.